Improving organs-at-risk sparing for choroidal melanoma patients: A CT-based two-beam strategy in ocular proton therapy with a dedicated eyeline.
Eyeline
Imaging-based
Multi-beam
Proton therapy
Uveal melanoma
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
19
01
2022
revised:
20
04
2022
accepted:
21
04
2022
pubmed:
30
4
2022
medline:
9
6
2022
entrez:
29
4
2022
Statut:
ppublish
Résumé
To investigate the potential clinical benefit of a two-beam arrangement technique using three-dimensional (3D) imaging of uveal melanoma (UM) patients treated with proton therapy and a dedicated eyeline. Retrospective CT-based treatment plans of 39 UM patients performed using a single beam (SB) were compared to plans with two beams (TB) optimized for better trade-offs in organs-at-risk sparing. The RBE-weighted prescribed dose was 60 Gy (D All strategies resulted in dosimetrically acceptable plans. A dose reduction to the anterior structures was achieved in 23/39 cases with the two-beam plans. D A two-beam strategy appears beneficial for posterior tumors abutting the optic nerve. This strategy might have a positive impact on the risk of ocular complications.
Identifiants
pubmed: 35487435
pii: S0167-8140(22)00227-4
doi: 10.1016/j.radonc.2022.04.021
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
173-181Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest This research was co-funded by the research program PROTONS4Vision (Grant NWO 14654), which is financed by the Netherlands Organization for Scientific Research (NWO), Technology Foundation STW, the Top consortium for Knowledge & Innovation (TKI-HTSM), and Varian Medical Systems Particle Therapy GmbH & Co. KG, Troisdorf, Germany.